Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Basic) (2016 - 2025)

IGC Pharma (IGC) has disclosed EPS (Basic) for 15 consecutive years, with -$0.02 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 33.33% to -$0.02 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.07, a 65.0% increase, with the full-year FY2025 number at -$0.09, up 59.09% from a year prior.
  • EPS (Basic) was -$0.02 for Q3 2025 at IGC Pharma, roughly flat from -$0.02 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q1 2025 to a low of -$0.09 in Q3 2021.
  • A 4-year average of -$0.04 and a median of -$0.04 in 2021 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 125.0% in 2021, then skyrocketed 79.6% in 2025.
  • IGC Pharma's EPS (Basic) stood at -$0.05 in 2021, then crashed by 80.0% to -$0.09 in 2023, then surged by 77.78% to -$0.02 in 2024, then rose by 0.0% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for IGC's EPS (Basic) are -$0.02 (Q3 2025), -$0.02 (Q2 2025), and -$0.01 (Q1 2025).